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BACKGROUND
Chronic obstructive pulmonary disease (COPD) is an important
cause of morbidity and mortality with high social and
economic costs. The prevalence of COPD has been reported to
vary between 6 and 26.1% worldwide.1 COPD has also been
associated with a high prevalence of one or more comorbid
conditions, which have an impact on health status and
mortality.2–5 Although several diseases have been studied as
COPD comorbidities6,7 few studies have looked at the issue of
multimorbidity in COPD.8–10
COPD, like other chronic disorders, has been associated with
comorbidities that increase in number and severity with age, and
are more prevalent among deprived social groups.5,8
There is evidence that comorbidities increase the risk for
exacerbations, reduce health status, and increase the risk of
mortality.5,8 COPD guidelines (e.g., GOLD recommendations)
still consider the diagnosis and management of comorbidities
from an individual disease point of view.11 Consequently,
health services focus on individual diseases rather than
multimorbidity.10–13 A better knowledge of the prevalence and
impact of multimorbidity facing COPD patients in primary
care would help to evaluate whether a different approach
(i.e., multimorbidity) should be taken.
Research on the prevalence of comorbidities among patients
with COPD and their impact on health status in primary care
patients is scarce. Most studies that evaluated the spectrum and
prevalence of comorbidities affecting COPD patients have been
conducted in secondary care settings. For example, Divo et al.4
found a relationship between comorbidities and the risk of death
over 51 months. Anxiety, cancers, and heart diseases are among
the most signiﬁcant comorbid diseases associated with COPD
mortality risk in secondary care settings.4 Increasing knowledge
about COPD comorbidities in primary care is essential for the
development of better intervention strategies and for reframing
clinical guidelines.
This is a unique opportunity to evaluate the impact of individual
comorbidities and multimorbidity on COPD patients in primary
care in different settings.
AIMS
To determine the prevalence of comorbid conditions in COPD
patients, and to assess their association on the health status and
on COPD symptoms in primary care patients in a range of settings
across Europe. This study will address the following research
questions:
1. What is the prevalence of comorbid conditions in COPD
patients in real-life primary care?
2. Is there an association of one or more comorbid conditions
with health status and with COPD symptoms in different
primary care cohorts?
METHODS
Design
The study involves a cross-sectional analysis of primary care data
sets from different countries across Europe. At least eight data sets
will be included in the analysis.
Inclusion/exclusion criteria
Members of the UNLOCK Group of the International Primary Care
Respiratory Group (IPCRG)14 with cross-sectional data from
primary care settings15,16 will be invited to participate in the
study. Data sets will be eligible for inclusion if they are broadly
representative of the primary care settings of the community of
origin and include the required variables (see below). Patients
should have a general practitioner (GP) diagnosis of COPD.
Data collection
Required data variables for participation include the following:
● Age
● Gender
● Lung function (i.e., forced expiratory volume in one second
(FEV1) (% of predicted) and FEV1/FVC (forced vital capacity)-
ratio), if available
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● COPD disease-speciﬁc health status assessed by the Clinical
COPD Questionnaire (CCQ)17 and/or by the COPD Assessment
Test (CAT)18
● Medical Research Council (MRC) dyspnoea scale19
● Body mass index
● Smoking status (never, ex-smoker, and current)
● Educational level as a proxy for socio-economic status
● Data on comorbidities
1. Heart failure, ischaemic heart disease (or ‘heart disease’)
2. Hypertension
3. Diabetes
4. Depression
5. Asthma
6. If available: osteoporosis, anxiety, sleep apnoea, rheumatic
disease, cancer, rhinitis, stroke, dementia, and anaemia.
Data may be collected in various ways and will be clearly
reported and accounted for in the analyses, if appropriate.
Primary outcome
The primary outcome will be COPD disease-speciﬁc health status
assessed using the CCQ and/or CAT.
Data analysis
The cohorts are derived from heterogeneous settings and
countries, and therefore the data sets will not be combined, but
the results will be analysed and presented separately. Data will
initially be presented using descriptive statistics with graphical
display. Missing values will be identiﬁed and excluded from the
analysis with pairwise deletion. Differences between groups
(based on the number of comorbid conditions) in health status
measures (CCQ and/or CAT) and in COPD symptoms measure
(MRC score) will be tested with factorial analysis of covariance
(ANCOVA) models adjusting for important potential confounders
(e.g., age, sex, smoking status, and disease severity). Estimated
marginal means will be compared across data sets.
The χ2-test will be used to analyse differences in the prevalence
of comorbidities. Predictive associations between variables will be
studied with binary logistic regression models, and odds ratios
and respective conﬁdence intervals (e.g., 95%) will be reported.
Statistical signiﬁcance will be considered for P values o0.05.
The uncertainty of estimates, whenever possible, will be quantiﬁed
in terms of conﬁdence interval (e.g., 95%), and effect size
values (e.g., r2, Partial Eta Squared) will also be analysed,
interpreted, and reported. The analysis will be performed by
the UNLOCK researcher. Analyses will be performed using SPSS,
Version 20.0 (SPSS Inc, Chicago, IL, USA).
A sample size calculation is not applicable here, given that the
study will be conducted by comparison of data from different
samples that have already been collected. The known sample sizes
will provide sufﬁcient statistical power for even the very small
effect sizes. For example, the values for a very small effect size
such as d= 0.15 (Cohen’s effect size for means difference) will
require a sample of 1,500 patients for 90% statistical power: For
d= 0.35, a sample size of 250 will be required for the same
statistical power.
Ethical approval
All included data sets must be approved by the ethics committees
according to national law.
Participants identiﬁed in the data sets will remain anonymous,
and patient conﬁdentiality will be assured in the collection and
merging of the data sets.
SHORT DISCUSSION
The diagnosis and management of comorbid conditions in
COPD has important effects on exacerbations, health status,
and mortality.2–5 However, there is insufﬁcient knowledge about
the prevalence and impact of more than one comorbid
condition in COPD patients in primary care settings.8 Knowledge
of comorbidities in COPD and a better understanding of their
impact on health status may help to inform clinical practice and
healthcare service delivery.9,10
Although recent GOLD updates recognise the need to assess
health status and include it together with FEV1 and exacerbations
in the management algorithm, suggestions about comorbidities
are limited to the recommendation that guidelines should be
followed for each disease separately.11 However, it is well known
that health status is only weakly associated with spirometric
values20 such as the FEV1, and that some comorbidities as
depression and anxiety are the factors that more strongly
correlate with health status.21 It is expected that this study will
show to what extent other diseases or clusters of diseases also
inﬂuence health status and will consequently inform our approach
to COPD management.
In addition, this study of comorbidities will provide new insight
into the development of preventive interventions, the reduction
of burden of disease, and the adjustment of healthcare services to
meet patients’ needs in primary care. Expected results will provide
knowledge about the prevalence of comorbidities in COPD, and
their impact on health status between genders, age groups, and
countries. We also expect that the result from this study, and
future research on how and which multiple conditions affect
patients’ health status could be used to achieve a truly patient-
centred care.
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